Bullish Integra LifeSciences Holdings Insiders Loaded Up On US$2.50m Of Stock
Bullish Integra LifeSciences Holdings Insiders Loaded Up On US$2.50m Of Stock
Quite a few insiders have dramatically grown their holdings in Integra LifeSciences Holdings Corporation (NASDAQ:IART) over the past 12 months. An insider's optimism about the company's prospects is a positive sign.
在過去的12個月裏,很多內部人士大幅增持了納斯達克(Integra LifeSciences Holdings Corporation,NASDAQ:IART)的股票。內部人士對公司前景的樂觀是一個積極的信號。
While we would never suggest that investors should base their decisions solely on what the directors of a company have been doing, we do think it is perfectly logical to keep tabs on what insiders are doing.
雖然我們絕不建議投資者僅基於公司董事所做的事情來作出決策,但我們認爲密切關注內部人士所做的事情是完全合理的。
Integra LifeSciences Holdings Insider Transactions Over The Last Year
在過去的十二個月中,Integra LifeSciences控股公司的最大單筆內部交易是總裁Jan De Witte以每股38.50美元的價格購買30萬美元的股票。這意味着內部人士認爲每股39.11美元的當前價格很有吸引力。這意味着他們過去一直對公司持樂觀態度,儘管他們可能已經改變了他們的想法。我們總是喜歡看到內部人員購買,但值得注意的是,如果那些購買是以遠低於今天的股價進行的,那麼折扣價值可能隨着價格上漲而縮小。很高興的是,Integra LifeSciences Holdings的內部人員決定以接近當前股價的價格購買股票。
In the last twelve months, the biggest single purchase by an insider was when Executive Chairman Stuart Essig bought US$1.5m worth of shares at a price of US$28.49 per share. That means that an insider was happy to buy shares at above the current price of US$20.37. Their view may have changed since then, but at least it shows they felt optimistic at the time. To us, it's very important to consider the price insiders pay for shares. As a general rule, we feel more positive about a stock if insiders have bought shares at above current prices, because that suggests they viewed the stock as good value, even at a higher price.
在過去的12個月裏,一位內部人士最大的單筆購買是當時的執行主席Stuart Essig以28.49美元每股的價格買進了價值150萬美元的股票。這意味着內部人士願意以高於目前股價20.37美元的價格購買股票。他們的觀點可能已經改變,但至少這表明他們當時感到樂觀。對我們來說,考慮內部人士購買股票的價格非常重要。作爲一個普遍規律,如果內部人士以高於目前股價購買股票,我們對這隻股票的看法更爲積極,因爲這表明他們認爲這隻股票具有良好的價值,即使價格較高。
Over the last year, we can see that insiders have bought 88.99k shares worth US$2.5m. On the other hand they divested 1.19k shares, for US$26k. In total, Integra LifeSciences Holdings insiders bought more than they sold over the last year. You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below. By clicking on the graph below, you can see the precise details of each insider transaction!
在過去一年中,我們可以看到內部人士購買了價值250萬美元的8.899萬股股票。另一方面,他們賣出了0.119萬股股票,總價值爲2.6萬美元。總體來說,Integra LifeSciences Holdings的內部人士在過去一年裏購買的股票多於銷售的股票。您可以在下面的圖表中看到過去一年內的內部交易(由公司和個人)情況。點擊下面的圖表,您可以查看每次內部交易的詳細情況!
![1724412532739](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240823/42798876-0-87b2dfd7e9c06e57a5c540a39fae910b.webp/bigjpg)
There are plenty of other companies that have insiders buying up shares. You probably do not want to miss this free list of undervalued small cap companies that insiders are buying.
還有很多其他的公司,公司的內部人士正在購買股票。你可能不想錯過這個免費的小市值公司的低估列表。
Insiders At Integra LifeSciences Holdings Have Sold Stock Recently
英特格拉生命科學控股公司的內幕人士最近出售了股票
We have seen a bit of insider selling at Integra LifeSciences Holdings, over the last three months. Senior VP of Finance & Principal Accounting Officer Jeffrey Mosebrook sold just US$26k worth of shares in that time. It's not great to see insider selling, nor the lack of recent buyers. But the selling simply isn't sufficiently substantial to be of much use as a signal.
在過去三個月裏,我們看到英特格拉生命科學控股公司的內部人士有一些股票出售。財務副總裁兼首席會計師Jeffrey Mosebrook在那段時間內僅出售了價值2.6萬美元的股票。看到內幕人士出售股票並且最近沒有買家的情況並不好。但這種出售行爲並不足夠大,無法作爲一個有效的信號。
Does Integra LifeSciences Holdings Boast High Insider Ownership?
英特格拉生命科學控股公司是否擁有高比例的內部持股?
Another way to test the alignment between the leaders of a company and other shareholders is to look at how many shares they own. Usually, the higher the insider ownership, the more likely it is that insiders will be incentivised to build the company for the long term. Integra LifeSciences Holdings insiders own about US$55m worth of shares. That equates to 3.4% of the company. This level of insider ownership is good but just short of being particularly stand-out. It certainly does suggest a reasonable degree of alignment.
另一種測試公司領導人與其他股東之間一致性的方法是查看他們擁有的股份。通常,內部持股比例越高,內部人士越有動力爲長期發展建設公司。Integra LifeSciences控股公司的內部持股約佔價值5500萬美元的股份。這相當於公司的3.4%。這樣的內部持股水平很好,但還不夠引人注目。它確實表明了合理的一致性程度。
What Might The Insider Transactions At Integra LifeSciences Holdings Tell Us?
英特格拉生命科學控股的內部交易告訴我們什麼?
We did not see any insider buying in the last three months, but we did see selling. But the sales were small, so we're not concerned. But insiders have shown more of an appetite for the stock, over the last year. Insiders do have a stake in Integra LifeSciences Holdings and their transactions don't cause us concern. So while it's helpful to know what insiders are doing in terms of buying or selling, it's also helpful to know the risks that a particular company is facing. Be aware that Integra LifeSciences Holdings is showing 3 warning signs in our investment analysis, and 1 of those is a bit concerning...
我們在過去三個月沒有看到任何內部購買交易,但我們看到了賣出交易。但是銷售額很小,所以我們並不擔心。但內部人士在過去一年裏對該股有更多興趣。內部人士確實持有Integra LifeSciences控股公司的股份,他們的交易並沒有引起我們的擔憂。所以雖然了解內部人士在買入或賣出方面的行爲是有幫助的,但了解特定公司面臨的風險也是有幫助的。請注意,Integra LifeSciences控股公司在我們的投資分析中顯示了3個警示信號,其中有1個有點令人擔憂...
Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.
當然,您可能會在其他地方找到一項出色的投資。因此,請查看此免費的有趣公司列表。
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.
對於本文而言,內部人是指向相關監管機構報告其交易的個人。我們目前僅考慮公開市場交易和直接利益的私人處置,但不包括衍生交易或間接利益。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對本文有任何反饋?對內容有任何疑慮?請直接與我們聯繫。或者,發送電子郵件至editorial-team@simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。